Abstract
Tyrosine kinase inhibitors (TKI) are the standard of care in patients with Non Small cell lung cancer (NSCLC) harbouring EGFR mutations (EGFRm). Although nowadays the treatment of choice are the 3rd generation inhibitors, in developing countries there is still a low accessibility. It has not been resolved if there is any particular subgroup of patients that could benefit with sequential treatment, looking for prognostic factors and mechanisms underlying resistance is crucial to improve the choice of treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
